Free Trial
NASDAQ:RAPP

Rapport Therapeutics (RAPP) Stock Price, News & Analysis

Rapport Therapeutics logo
$12.04 +0.24 (+2.03%)
As of 07/3/2025 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Rapport Therapeutics Stock (NASDAQ:RAPP)

Key Stats

Today's Range
$11.95
$12.57
50-Day Range
$8.40
$13.16
52-Week Range
$6.43
$29.74
Volume
60,888 shs
Average Volume
164,404 shs
Market Capitalization
$439.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.00
Consensus Rating
Buy

Company Overview

Rapport Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
27th Percentile Overall Score

RAPP MarketRank™: 

Rapport Therapeutics scored higher than 27% of companies evaluated by MarketBeat, and ranked 2035th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Rapport Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Rapport Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Rapport Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Rapport Therapeutics are expected to grow in the coming year, from ($3.65) to ($3.37) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Rapport Therapeutics is -3.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Rapport Therapeutics is -3.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Rapport Therapeutics has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Rapport Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    16.26% of the float of Rapport Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Rapport Therapeutics has a short interest ratio ("days to cover") of 15.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Rapport Therapeutics has recently increased by 8.02%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Rapport Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Rapport Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    16.26% of the float of Rapport Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Rapport Therapeutics has a short interest ratio ("days to cover") of 15.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Rapport Therapeutics has recently increased by 8.02%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Rapport Therapeutics this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    2 people have added Rapport Therapeutics to their MarketBeat watchlist in the last 30 days.
Receive RAPP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rapport Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RAPP Stock News Headlines

Breakthroughs Backed by Wall Street - This image is an original composition by MarketBeat using licensed and editorial elements. Not for redistribution or reuse.
Analysts Can't Get Enough of These Little-Known Biopharma Stocks (RAPP)
Three relatively unknown biopharma firms receive near-unanimous approval from analysts for their promising drug candidates in development.
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
See More Headlines

RAPP Stock Analysis - Frequently Asked Questions

Rapport Therapeutics' stock was trading at $17.74 at the beginning of 2025. Since then, RAPP stock has decreased by 32.1% and is now trading at $12.04.

Rapport Therapeutics, Inc. (NASDAQ:RAPP) posted its quarterly earnings data on Thursday, May, 8th. The company reported ($0.68) EPS for the quarter, beating analysts' consensus estimates of ($0.77) by $0.09.

Rapport Therapeutics (RAPP) raised $136 million in an initial public offering (IPO) on Friday, June 7th 2024. The company issued 8,000,000 shares at $17.00 per share.

Shares of RAPP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Rapport Therapeutics investors own include Alpha Metallurgical Resources (AMR), Arch Biopartners (ARCH), Global X Copper Miners ETF (COPX), Hims & Hers Health (HIMS), Karuna Therapeutics (KRTX), Longboard Pharmaceuticals (LBPH) and Navios Maritime Partners (NMM).

Company Calendar

Last Earnings
5/08/2025
Today
7/04/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RAPP
Previous Symbol
NASDAQ:RAPP
Web
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$28.00
High Stock Price Target
$28.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+132.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$78.31 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$8.35 per share
Price / Book
1.44

Miscellaneous

Free Float
N/A
Market Cap
$439.46 million
Optionable
N/A
Beta
N/A
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:RAPP) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners